Bio-Techne Escapes A Slow Lab Market

Bio-Techne is making its escape from a difficult life-sciences market with an $11.3 billion deal. Germany’s Merck KGaA agreed to purchase the Minneapolis-based lab tools company for $73 per share in cash, giving Bio-Techne shareholders a sizable premium and giving Merck a bigger foothold in some of the fastest-growing corners of life sciences. Bio-Techne shares jumped about 20% Thursday, as investors saw the acquisition as a way out of a market that has been more petri dish than payday.

The timing is doing a lot of work here. Life-sciences tools companies have been stuck in a frustrating post-pandemic hangover, with weak biotech funding, cautious lab spending, and slower customer activity weighing on valuations. That made Bio-Techne more affordable than it might have been a few years ago, but it also made the deal more interesting. Merck is not buying a company at peak-market heat. It is buying a specialized supplier of reagents, proteins, antibodies, analytical instruments, and precision-diagnostics tools at a moment when the sector is still trying to get its groove back.

Merck's pitch is that Bio-Techne fills in important gaps across the research and drug-development chain. The company brings exposure to multi-omics, spatial biology, cell and gene therapy, precision diagnostics, and bioprocessing workflows — all areas where drugmakers and researchers are dealing with more complex science and higher technical demands. Merck also expects about €140 million in annual cost synergies by the third year after closing, giving the deal a financial framework beyond simply paying up for a better product catalog.

The risk is that Merck is still writing an $11 billion check for a business tied to end markets that have not fully snapped back. The transaction still needs Bio-Techne shareholder approval and regulatory clearances, and it is not expected to close until late 2026 or early 2027. Still, the message from the deal is pretty clear. High-quality lab tools assets are worth buying, even in a weak market. Bio-Techne waited out the slowdown long enough to get a premium, and Merck is betting the next life-sciences rebound will be easier to capture with Bio-Techne on board.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726